Daeiou Pharmaceuticals Private Limited - Due diligence report

A 360° intelligence report on Daeiou Pharmaceuticals Private Limited: trust score, financial health, credit view, compliance, directors, gro…

2009-10-21 Pondicherry, Pondicherry Active Unlisted Active Compliant
Share
Connect MCP
DP Daeiou Pharmaceuticals Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Daeiou Pharmaceuticals Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
74/100
Trust Score
Moderate

Daeiou Pharmaceuticals Private Limited is assessed as Moderate with a Trust Score of 74/100. Daeiou Pharmaceuticals Private Limited is an active private limited indian non-government company incorporated in 2009, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and moderate financial risk profile.

Report generated on 02 Aug 2026 from the latest processed filings. Daeiou Pharmaceuticals Private Limited snapshot & full profile →

Financial Health › Good
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
74/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
74/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
65/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
55/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
75/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
70/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
65/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 55/100 Moderate
  • Negative operating earnings - debt service depends on external support.
  • Moderate gearing (D/E 38%).
  • Working-capital cover adequate.

Charges position: 3 open (7.25 cr) · 0 satisfied (-).

Banking relationships (from registered charges)
LenderChargesAmount
Others2 48.0 cr
Indian Overseas Bank1 48.0 cr
Compliance Score: 74/100 Moderate
  • Company status is Active as per MCA.
  • Balance sheet slightly behind (Mar 2024).
  • Litigation present in 2 court forum(s).
  • 1 active GST registration(s).
Legal cases on record (2)
05

Director Intelligence

Stability score: 75/100
NameDIN / PANDesignationAppointedTenureDIN status
CHITRAH RANGASAMY 01234567 Director 01/04/2018 6 yrs Approved
Nalliyappan Shanmugapriya 01234567 Director 01/04/2018 6 yrs Approved
ARULJOTHI SRINIVASAN 01234567 Director 01/04/2018 6 yrs Approved
ELAMURUGARAJA MUTHUSAMY 01234567 Director 01/04/2018 6 yrs Approved
Sengottuvel 01234567 Director 01/04/2018 6 yrs Approved
VIVEKANANDAN SUMATHI 01234567 Director 01/04/2018 6 yrs Approved
MUTHUMANI THRISHA SEN 01234567 Director 01/04/2018 6 yrs Approved
NATESAN SENTHILKUMAR 01234567 Director 01/04/2018 6 yrs Approved
MURUGESAN JAYAKUMAR 01234567 Director 01/04/2018 6 yrs Approved
CHINNASAMY 01234567 Director 01/04/2018 6 yrs Approved
Manisha Singh 01234567 Director 01/04/2018 6 yrs Approved
Jayanthi Ravi Madhuritha 01234567 Director 01/04/2018 6 yrs Approved
Palanichamy Vinoth Kumar 01234567 Director 01/04/2018 6 yrs Approved
  • 13 directors on the board.
  • No disqualified or deactivated DINs.
  • 5 director exits in 3 years - high churn.
Director & KMP remuneration (FY 2023)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
25 allotment(s) · 0 transfer(s)

Promoters hold the largest single block of equity - exact percentages are part of the full report.

Key managerial personnel: MURUGESAN JAYAKUMAR (Managing Director)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 70 · Distress 65
Growth signals & trust indicators
Steady revenue growth: +1.42 over 4 year(s).
Asset base grew 2.1x - capacity expansion.
EPFO headcount growing - hiring signal.
Operating for 16+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Losses deepening year-on-year.
3 director exits within 2 years.
3 open charge(s) registered - assets are encumbered.
2 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence71/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 2 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment63/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 3 open charge(s) of 7.25 cr already registered.
  • Compliance record supports lending.
Investor view69/100
Mixed indicators
Growth quality and scalability through an investor lens.
  • 3 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
26 Dec 2025
Director appointed
Palanichamy Vinoth Kumar (Ceo)
06 Oct 2025
Director appointed
Jayanthi Ravi Madhuritha (Additional Director)
29 Sep 2025
Director ceased
CHITRAH RANGASAMY
Director ceased
Sengottuvel
30 Apr 2025
Director appointed
Manisha Singh (Company Secretary)
10 Mar 2025
Director appointed
CHITRAH RANGASAMY (Director)
Director appointed
Sengottuvel (Director)
03 Oct 2024
Director ceased
RAGHURAMAN PARTHASARATHY
30 Sep 2024
Last AGM held
Annual general meeting
20 Aug 2024
Charge created
Others - 3.35 cr
Charge created
Others - 3.50 cr
10 Jul 2024
Director ceased
RAMASAMY KANAGARAJ
31 Mar 2024
Latest balance sheet
Filed with ROC
18 Aug 2023
Director ceased
AISHWARYA NEELAMOHAN
06 Jul 2023
Director appointed
Nalliyappan Shanmugapriya (Director)
10

Key Observations

Auto-generated from the data above
Revenue grew 24% over the last 4 financial year(s).
Net profit margin moved from 0.86 to 61%.
Debt-to-equity stands at 38% - manageable leverage.
Net worth is positive.
13 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold the largest single block of equity as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 25 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Alchemist Remedies Private Limited U24230MP2009PTC022487 Indore, Madhya Pradesh, India
Mohata Enterprises Private Limited U24119WB1998PTC086359 Kolkata, West Bengal, India
Kankoo Paints Pvt Ltd U24222PN1992PTC066651 Khed Shivapur, Maharashtra, India
Sunlight Paints Private Limited U24111GJ2000PTC037330 Antalia, Gujarat, India
Supermax Industries Private Limited U25111DL1998PTC092874 New Dlhi, Delhi, India
Vardhaman Dye-Stuff Industries Private Limited U24110MH1992PTC066725 Mumbai, Maharashtra, India
Barsana Pharma Private Limited U24110AP2009PTC081665 Visakhapatnam, Andhra Pradesh, India
Divakar Techno Specialities & Chemicals Private Limited U24230MH1991PTC063555 Goregaon East, Maharashtra, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Daeiou Pharmaceuticals Private Limited before audits and certifications: compliance score 74/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Daeiou Pharmaceuticals Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 55/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Mixed indicators. Growth score 70/100, margin trends, ownership structure and peer set for Daeiou Pharmaceuticals Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 74/100, distress signals and MSME payment-delay disclosures - know whether Daeiou Pharmaceuticals Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (2 case(s) on record), regulatory flags, charge documents trail and director networks for Daeiou Pharmaceuticals Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Daeiou Pharmaceuticals Private Limited an active company?

Daeiou Pharmaceuticals Private Limited has MCA status “Active” with a compliance score of 74/100 (Moderate).

Is Daeiou Pharmaceuticals Private Limited financially healthy?

Daeiou Pharmaceuticals Private Limited has a Financial Health Score of 65/100 (Moderate) based on its filed financial statements.

Should I do business with Daeiou Pharmaceuticals Private Limited?

Its overall Trust Score is 74/100 (Moderate). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Daeiou Pharmaceuticals Private Limited?

Promoters hold the largest single block of equity - exact percentages are in the full report. 13 active director(s) are on record.

Does Daeiou Pharmaceuticals Private Limited have loans or charges against its assets?

3 open charge(s) are registered against its assets.

Is Daeiou Pharmaceuticals Private Limited up to date with its ROC filings?

Balance sheet slightly behind (Mar 2024). Overall compliance score: 74/100 (Moderate).

Is it risky to lend to Daeiou Pharmaceuticals Private Limited?

Its Credit Risk Score is 55/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.